OmniAb (NASDAQ:OABI) Releases Earnings Results

OmniAb (NASDAQ:OABI) released its quarterly earnings data on Tuesday. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01, Zacks reports. OmniAb had a negative net margin of 308.78% and a negative return on equity of 20.97%.

OmniAb Stock Up 0.6 %

Shares of OABI traded up $0.02 during trading hours on Tuesday, reaching $3.19. 511,112 shares of the company traded hands, compared to its average volume of 515,927. The company’s fifty day moving average price is $3.42 and its two-hundred day moving average price is $3.81. The company has a market capitalization of $450.48 million, a price-to-earnings ratio of -5.15 and a beta of -0.14. OmniAb has a 12 month low of $3.05 and a 12 month high of $5.72.

Insider Activity

In related news, CEO Matthew W. Foehr sold 41,811 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total transaction of $135,467.64. Following the sale, the chief executive officer now owns 3,749,639 shares of the company’s stock, valued at $12,148,830.36. The trade was a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Charles S. Berkman sold 25,489 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total transaction of $82,584.36. Following the sale, the insider now directly owns 343,190 shares in the company, valued at $1,111,935.60. The trade was a 6.91 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 112,260 shares of company stock valued at $376,601. Corporate insiders own 8.60% of the company’s stock.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.